GlassScriptPhysician profile
Charlene S Shookoff
NPI 1669435483
$16,546.84
in general payments reported to CMS, 2019-2025
30 companies · $1,294 in 2025
The $1,294 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,749 · 2020: $1,062 · 2021: $2,572 · 2022: $2,978 · 2023: $4,201 · 2024: $2,691 · 2025: $1,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,118 · Education: $67.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,117.60 |
| Education | $67.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,468.26 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $2,720.93 | 2019-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $1,942.34 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,435.41 | 2019-2024 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $1,183.42 | 2020-2024 | Takhzyro, Hyqvia, Glassia |
| Pfizer INC. | $797.54 | 2019-2024 | |
| Optinose US, INC. | $672.15 | 2019-2024 | |
| Csl Behring | $530.97 | 2019-2023 | Haegarda, Hizentra |
| Genentech USA, INC. | $356.34 | 2019-2025 | Xolair |
| Leo Pharma INC. | $343.51 | 2022-2024 | Adbry |
| Amgen INC. | $300.84 | 2023-2024 | Tezspire |
| Incyte Corporation | $250.87 | 2022-2023 | Opzelura |
| Biocryst US Sales Co., LLC | $220.19 | 2022-2024 | Orladeyo |
| Alk-Abello, INC | $174.69 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $141.01 | 2019-2024 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $137.54 | 2022-2024 | |
| Ionis Pharmaceuticals, INC. | $121.98 | 2025 | Dawnzera |
| Sanofi US Services INC. | $119.81 | 2025 | |
| Aimmune Therapeutics, INC. | $119.47 | 2020-2022 | |
| Teva Pharmaceuticals USA, INC. | $97.35 | 2019-2021 | |
| Grifols Shared Services North America, INC. | $94.43 | 2024 | Xembify |
| Kaleo, INC. | $86.15 | 2019-2024 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.29 | 2021-2022 | |
| Octapharma USA, INC. | $29.69 | 2019 | |
| Grifols USA, LLC | $28.53 | 2019 | |
| Invivyd INC | $28.41 | 2025 | Pemgarda |
| Mylan Specialty L.P. | $27.09 | 2021 | |
| Shire North American Group INC | $17.61 | 2019 | |
| Pharming Healthcare, INC. | $17.27 | 2021 | |
| Sunovion Pharmaceuticals INC. | $16.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charlene Shookoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.